We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




AACC Competition Demonstrates How Labs Can Use Data Analytics to Solve Real Problems

By LabMedica International staff writers
Posted on 17 Oct 2022

Clinicians rely on parathyroid hormone-related peptide (PTHrP) measurement to help establish a diagnosis of humoral hypercalcemia of malignancy - a rare form of cancer that causes, among other things, high levels of calcium in the blood. More...

The problem: Clinicians often order it for patients with low pretest probability. Excessive PTHrP testing can lead to expensive, unnecessary, and potentially harmful procedures, including invasive laboratory testing to locate a possibly nonexistent cancerous tumor. A successful predictive algorithm would help laboratorians quickly and accurately identify potentially inappropriate PTHrP test orders by predicting whether laboratory data available at the time of order already suggest an abnormal PTHrP result. A machine-learning challenge introduced for the first time by the American Association for Clinical Chemistry (Washington, DC, USA; www.aacc.org) at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo demonstrated how laboratories can use data analytics to solve these real problems facing patients and clinicians.

The Predicting PTHrP Results Competition introduced by the AACC at the event in association with the informatics section in the department of pathology and immunology of Washington University School of Medicine, St. Louis (WUSM, St. Louis, MI, USA) aimed to engage the community of laboratory medicine practitioners in a fun and friendly online environment where they could practice their data analytics skills, learn from each other, and see how others approach problems on the data-driven side of laboratory medicine. Competition participants formed teams and used securely shared real, de-identified clinical data from PTHrP orders at WUSM to build their predictive algorithms. This is termed the “practice dataset”. Using real clinical data was a big deal because most machine-learning competitions use synthesized datasets. Organizers set up the competition using Kaggle, a popular online platform for machine-learning modeling and contests, and selected F1 score (the harmonic mean of sensitivity and specificity) as the performance metric.

A major challenge for the teams was developing a predictive model that achieved high accuracy without overfitting it to the public dataset (the practice dataset). Overfitting would mean the algorithm worked well on the initial data but failed if applied to new data and was not generalizable. Organizers used a second, private dataset to judge the algorithm’s effectiveness. From May to June 2022, 24 teams ran a total of 395 iterations of their predictive models through the public dataset. Each time a team submitted a predictive model for an attempt, they used the resulting F1 score to improve - or “train” - the model. For the final attempt, each team ran their predictive model through the private dataset. The winning team, Team Kagglist, achieved an F1 score of 0.9 with their predictive model. For reference, WUSM’s manual approach for identifying patients at risk for PTHrP had an F1 score of 0.6, making the algorithm a significant improvement over standard practice.

“We shouldn’t expect a predictive model trained on data from one hospital to automatically work at other hospitals,” said Team Kaggle’s Yingheng Wang. “Ultimately, we should aim to create adaptive models that can be fine-tuned by other institutions for their specific populations.”

“The quality of all 24 models was excellent and showed a high degree of accuracy for the very difficult task we challenged participants with,” said competition organizer Mark Zaydman, MD, PhD, an assistant professor of pathology and immunology at WUSM. “This competition really showed our community is ready to engage with sophisticated machine learning and data analytics tools.”

Related Links:
AACC 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.